Commercial Marketing interview prep.

Brand directors, marketing managers, launch leads, market access + HEOR (health economics + outcomes research), sales ops.

What interviewers look for

  • Can the candidate build a brand strategy grounded in clinical evidence + patient + HCP insight?
  • Do they understand market access + payer realities - formulary, prior auth, payer evidence asks, HEOR?
  • Are they fluent in HCP + patient + payer audiences + their distinct drivers?
  • Can they lead a cross-functional launch - field, medical, market access, commercial ops, compliance, legal?
  • Do they navigate compliance + regulatory constraints (PhRMA Code, OIG, off-label, PDUFA) without becoming paralysed?
  • Are they fluent in lifecycle thinking - LOE response, label expansion, biosimilar / generic competition?
  • Can they show evidence-based decision-making + comfort with the data even when the answer's hard?

Behavioural questions to expect

  1. Walk me through your background + commercial experience.

    What it tests: Story arc - relevant training (MBA / clinical / scientific), commercial / brand exposure, matrix experience.

  2. Tell me about a brand or launch you've led or significantly contributed to.

    What it tests: Commercial thinking - strategy, evidence-narrative connection, cross-functional execution, measurable outcome.

  3. Why pharma commercial + brand vs other commercial paths (FMCG, tech, consulting)?

    What it tests: Authentic alignment - patient impact, evidence-driven storytelling, complex multi-stakeholder.

  4. Why this therapeutic area?

    What it tests: Specificity. Generic answers fail.

  5. Why this firm?

    What it tests: Real homework - portfolio, recent moves, commercial culture - not name-drop.

  6. What's your read on our commercial portfolio + recent launches?

    What it tests: Industry literacy - asset performance, share, growth, competitive position.

  7. Tell me what you understand about our market access + payer strategy.

    What it tests: Market access fluency - formulary position, payer contracting, HEOR + RWE investment.

  8. Walk me through positioning + brand strategy for a specific asset.

    What it tests: Brand strategy thinking - patient + HCP insight + clinical evidence + competitive context = positioning.

Technical concepts to master

Positioning + evidence linkage

Patient + HCP insight
Qualitative + quantitative research into disease experience, decision drivers, unmet needs - foundation of strategy.
Clinical evidence translation
Translating clinical trial + RWE + HEOR into language + claims that HCP + patient + payer find compelling.
Positioning statement
Compact statement of [target audience], [core benefit], [reason-to-believe], [competitive context].
Reason to believe (RTB)
Specific evidence + features supporting the positioning claim.

Market access + payer strategy

Payer archetypes
Commercial payers, Medicare (Part B + D + MA), Medicaid, VA / DoD - distinct decision drivers + evidence asks.
Formulary decision + P&T
Pharmacy + Therapeutics Committee at payer reviews evidence + cost + outcomes to set formulary position.
Gross-to-net
Difference between list price + actual net realised - rebates, 340B, Medicaid, patient assistance, distribution fees.
Contracting + rebate strategy
Negotiated rebates with payers in exchange for preferred formulary or removed restrictions.

HEOR + RWE

HEOR (Health Economics + Outcomes Research)
Modelling cost-effectiveness, budget impact, productivity, quality of life - generates evidence payers + HTA bodies need.
Real-world evidence (RWE)
Evidence from healthcare data - claims, EHR, registry, patient-generated - on effectiveness + safety + utilisation.
ICER + value frameworks
Institute for Clinical + Economic Review - independent US value framework; NICE in UK; CADTH in Canada.
Patient-reported outcomes (PROs)
Patient-reported measures (HRQoL, symptom, function) supporting clinical + commercial evidence.

Compliance + PhRMA Code

PhRMA Code on Interactions with HCPs
Industry voluntary code governing HCP interactions - meals, education, samples, gifts.
Off-label communication restrictions
FDA restricts promotion to on-label use; off-label discussions allowed in unsolicited medical inquiry context via Med Affairs.
OIG + DOJ enforcement
OIG Office of Inspector General + DOJ enforce anti-kickback + False Claims Act on pharma.
Open Payments + Sunshine Act
Federal requirement to publicly report payments + transfers of value to HCPs.

Practical drills

  • You're the new brand lead for an asset just approved in a competitive market with 3 established competitors. Walk through your positioning strategy.
  • Your asset is 9 months from PDUFA. Walk through your pre-launch + launch plan - cross-functional sequencing + KPIs.
  • A major commercial payer just moved your asset from preferred to non-preferred, citing inadequate evidence vs comparator. Walk through your response.

Smart-question anchors

  • Portfolio + recent launches - asset performance, competitive position
  • Commercial org + matrix - brand / TA structure, cross-functional alignment
  • Market access posture - HEOR investment, contracting model, recent access events
  • Patient + HCP engagement - omni-channel, DTC, hub + services investment
  • Compliance + ethics culture - PhRMA Code adherence, recent enforcement experience

Related roles

Sourced from

Ready to Generate Your Own Prep?

Drop your CV and a job description on the home page. A couple of minutes later you get a report with everything you need to land the job.